BronchogenvsMK-677

Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.

For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.

As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Unlike peptide-based GH secretagogues that require injection, MK-677 is resistant to gastrointestinal degradation and has excellent oral bioavailability, making it unique among compounds that stimulate GH release through the ghrelin receptor.

Upon binding GHS-R1a in the anterior pituitary, MK-677 activates the Gq/11-coupled PLC/IP3/calcium signaling pathway, triggering GH vesicle exocytosis. It also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH neurons in the arcuate nucleus while suppressing somatostatin tone, further amplifying the GH secretory signal. Importantly, MK-677 preserves the endogenous pulsatile pattern of GH release — it amplifies pulse amplitude rather than creating a flat, sustained elevation.

The 24-hour half-life means a single daily dose maintains elevated GH and IGF-1 levels around the clock. In clinical studies, MK-677 increased IGF-1 levels by 40-60% in elderly subjects, with sustained effects over 12 months without significant tachyphylaxis. However, its ghrelin-mimetic activity also activates hypothalamic appetite circuits (orexigenic neurons expressing NPY/AgRP), producing the notable increase in hunger that many users report. The compound also has mild cortisol-raising effects and can impair insulin sensitivity with prolonged use, likely through sustained GH-mediated antagonism of insulin signaling in peripheral tissues. Despite promising clinical data for muscle wasting and osteoporosis, MK-677 has not completed the FDA approval process.